Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Baldeon
  SRCTN85216856		 RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
63/95 inconclusive
    ITAC
          NCT04546581    		 RCTneutralizing antibodyplaceboCOVID 19 hospitalizedsome concern
    		301/292 inconclusive
    • inconclusive 6 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
    trial did not meet its endpoints (press release)
    Bennett-Guerrero
          NCT04344535    		 RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
    		59/15 inconclusive
      CCAP-2
              NCT04345289      		 RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedlow
      		98/46 inconclusive
        CONTAIN COVID-19
                  NCT04364737        		 RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
        		468/473 inconclusive
        • inconclusive 6 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
        CPC-SARS
                  NCT04405310        		 RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedhigh
        		32/11 suggested
        • suggested 96 % decrease in deaths but with a low degree of certainty due to high risk of bias
        LACCPT
                  PACTR202006760881890        		 RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedNA
        		11/11 inconclusive
          NCT04442191
                      NCT04442191          		 RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedlow
          		8/6 inconclusive
            PLACO-COVID
                          NCT04428021            		 RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedNA
            		60/60 inconclusive

              COVID-19 mild to moderate meta-analysis

              Libster
                              NCT04479163              		 RCTconvalescent plasma treatmentplaceboCOVID-19 mild to moderatelow
              		80/80 conclusif
              • demonstrated 48 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias

              COVID-19 severe or critically meta-analysis

              O’Donnell
                              NCT04359810              		 RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
              		150/73 inconclusive
              • inconclusive 38 % increase in clinical improvement (28-day) (PE) with a high degree of certainty due to low risk of bias
              Gharebaghi
                              IRCT20200501047259N1              		 RCTimmunoglobulin therapy placeboCOVID-19 severe or criticallyNA
              		30/29 suggested
              • suggested 100 % decrease in deaths,death D28
              ILBS-COVID-02 (Bajpai M)
                              NCT04346446              		 RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallyhigh
              		14/15 inconclusive
              • inconclusive 74 % decrease in off oxygenation (PE) but with a low degree of certainty due to high risk of bias
              PlasmAr
                              NCT04344535              		 RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
              		228/106 inconclusive
              • inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias

              PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
              Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

               

              - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons